These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21734183)

  • 41. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy.
    Mercuri E; Coratti G; Messina S; Ricotti V; Baranello G; D'Amico A; Pera MC; Albamonte E; Sivo S; Mazzone ES; Arnoldi MT; Fanelli L; De Sanctis R; Romeo DM; Vita GL; Battini R; Bertini E; Muntoni F; Pane M
    PLoS One; 2016; 11(8):e0160195. PubMed ID: 27494024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating the Feasibility and Reliability of Remotely Delivering and Scoring the North Star Ambulatory Assessment in Ambulant Patients with Duchenne Muscular Dystrophy.
    Emery N; Strachan K; Kulshrestha R; Kuiper JH; Willis T
    Children (Basel); 2022 May; 9(5):. PubMed ID: 35626905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.
    Zambon AA; Ayyar Gupta V; Ridout D; Manzur AY; Baranello G; Trucco F; Muntoni F;
    Dev Med Child Neurol; 2022 Aug; 64(8):979-988. PubMed ID: 35385138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prednisolone in Duchenne muscular dystrophy.
    Rahman MM; Hannan MA; Mondol BA; Bhoumick NB; Haque A
    Bangladesh Med Res Counc Bull; 2001 Apr; 27(1):38-42. PubMed ID: 11692899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
    Connolly AM; Florence JM; Cradock MM; Malkus EC; Schierbecker JR; Siener CA; Wulf CO; Anand P; Golumbek PT; Zaidman CM; Philip Miller J; Lowes LP; Alfano LN; Viollet-Callendret L; Flanigan KM; Mendell JR; McDonald CM; Goude E; Johnson L; Nicorici A; Karachunski PI; Day JW; Dalton JC; Farber JM; Buser KK; Darras BT; Kang PB; Riley SO; Shriber E; Parad R; Bushby K; Eagle M;
    Neuromuscul Disord; 2013 Jul; 23(7):529-39. PubMed ID: 23726376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data.
    Pane M; Coratti G; Brogna C; Mazzone ES; Mayhew A; Fanelli L; Messina S; D'Amico A; Catteruccia M; Scutifero M; Frosini S; Lanzillotta V; Colia G; Cavallaro F; Rolle E; De Sanctis R; Forcina N; Petillo R; Barp A; Gardani A; Pini A; Monaco G; D'Angelo MG; Zanin R; Vita GL; Bruno C; Mongini T; Ricci F; Pegoraro E; Bello L; Berardinelli A; Battini R; Sansone V; Albamonte E; Baranello G; Bertini E; Politano L; Sormani MP; Mercuri E
    PLoS One; 2018; 13(6):e0199223. PubMed ID: 29924848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy.
    Parreira SL; Resende MB; Zanoteli E; Carvalho MS; Marie SK; Reed UC
    Arq Neuropsiquiatr; 2010 Oct; 68(5):683-8. PubMed ID: 21049175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
    Fang Y; McDonald CM; Clemens PR; Gordish HD; Illei K; Hoffman EP; ; Dang UJ
    J Neuromuscul Dis; 2023; 10(3):349-364. PubMed ID: 36806514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy.
    Hibma JE; Jayachandran P; Neelakantan S; Harnisch LO
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):375-386. PubMed ID: 36718719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progression of Ankle Plantarflexion Contractures and Functional Decline in Duchenne Muscular Dystrophy: Implications for Physical Therapy Management.
    Kiefer M; Bonarrigo K; Quatman-Yates C; Fowler A; Horn PS; Wong BL
    Pediatr Phys Ther; 2019 Jan; 31(1):61-66. PubMed ID: 30557283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Muscle MRI and functional outcome measures in Becker muscular dystrophy.
    Barp A; Bello L; Caumo L; Campadello P; Semplicini C; Lazzarotto A; Sorarù G; Calore C; Rampado A; Motta R; Stramare R; Pegoraro E
    Sci Rep; 2017 Nov; 7(1):16060. PubMed ID: 29167533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.
    Willcocks RJ; Rooney WD; Triplett WT; Forbes SC; Lott DJ; Senesac CR; Daniels MJ; Wang DJ; Harrington AT; Tennekoon GI; Russman BS; Finanger EL; Byrne BJ; Finkel RS; Walter GA; Sweeney HL; Vandenborne K
    Ann Neurol; 2016 Apr; 79(4):535-47. PubMed ID: 26891991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy.
    Parreira SL; Resende MB; Della Corte Peduto M; Marie SK; Carvalho MS; Reed UC
    Arq Neuropsiquiatr; 2007 Jun; 65(2A):245-50. PubMed ID: 17607422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.
    Coratti G; Pane M; Brogna C; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Hogrel JY; Straub V; De Lucia S; Niks E; Servais L; De Groot I; Chesshyre M; Bertini E; Goemans N; Muntoni F; Mercuri E;
    PLoS One; 2021; 16(6):e0253882. PubMed ID: 34170974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative electromyography in ambulatory boys with Duchenne muscular dystrophy.
    Verma S; Lin J; Travers C; McCracken C; Shah D
    Muscle Nerve; 2017 Dec; 56(6):1168-1171. PubMed ID: 28457006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.